Thus, rare CDH1 germline variants predicted to be deleterious co-segregated with the tumor phenotype, mostly with ODs, WHO grade II/III, in two of 15 (13.3%) glioma families, and their frequency was significantly lower in controls (1.7%). This evidence concerns the gene CDH1 and neoplasm.